Opportunities for Knowledge Transfer and Funding – Regen Med

Dr Sarah Goulding
Knowledge Transfer Manager, Medical Biotechnology and Regenerative Medicine

Bioprocessing for Advanced Therapies Group and amc Joint Meeting, Birmingham
7th February 2013
Building a Healthy Nation through Business Innovation

The HealthTech and Medicines KTN supports business innovations through partnerships, access to funding and knowledge transfer

Connecting Partners
- Bringing together & facilitating collaborations with a common goal

Access to Funding
- Identify and influence new and existing sources of funding

Knowledge Transfer
- Opening doors to wider networks of people/organisations
Health KTN Priority Areas

- Clinical Needs
- Emerging Medical Technologies
- Novel Therapies
- High Value Manufacturing
- Regenerative Medicine
- Synthetic Biology
- Detection and Identification of Infectious Agents
- Assisted Living Innovation Platform
- Stratified Medicine Innovation Platform
RegenMed Activity

- Support community engagement activities across the breadth of the RegenMed sector
- Work in partnership with regions, other networks and KTNs, industrially engaged academic groups and industry
- Link biologics bioprocessing agenda, and our other priority areas, to ensure they benefit RegenMed/Cell Therapy
- Identify KT gaps and address by catalysing community building
- Support development of partnerships involved in TSB funding
- Engage early career bioprocessing professionals in the RegenMed community
Bioprocessing for Advanced Therapies
- NHS BT Filton - Bristol, 2012
- AMC joint meeting today – Birmingham

Health KTN-Regener8-IKC Joint Workshop;
- Regenerative Therapies – the Med Tech route to Market
  - Opportunities for the Med Tech Industry
  - 25 April 2013, Sheffield

Clinical Need workshops
- Regen Med : New Collaboration Opportunities In Wound Care, Orthopaedic and Cardiovascular, 2012
Technology Strategy Board: Programmes

- Smart (Single Businesses)
- Knowledge Transfer Partnerships - KTPs
- Small Business Research Initiative (SBRI)
- Collaborative Research & Development
- Innovation Platforms
- Biomedical Catalyst
- Knowledge Transfer Networks
- Catapult Centres
Biomedical Catalyst

• Partnership TSB and MRC, fund of £180m
• Translating excellent science into clinical practice
• Three categories of grant:
  – Feasibility study award
  – Early stage award
  – Late stage award
• Open to UK SMEs and academic centres
• Addressing:
  – disease prevention and proactive management of health and chronic conditions
  – earlier and better detection and diagnosis of disease
  – highly effective treatments tailored to patients’ needs

• NEXT deadline NOON 28 February (register by 21st)
**Feasibility award**

This grant enables the exploration and evaluation of the commercial potential of an early-stage scientific idea, through:
- review of research evidence and identification of application
- assessment of business opportunity
- investigation of intellectual property position
- experimental studies to validate initial concepts or existing pre-clinical work
- scoping for further development.

**Key features**

**Business-led applications:**
- Duration – up to 12 months
- Maximum grant – £150k
- Funding proportion – up to 75% of total eligible project costs

**Academic-led applications:**
- Confidence in Concept Awards will be made available to researchers in major universities

**Early-stage award**

This grant is to evaluate the technical feasibility of an idea and establish proof of concept in a model system, through:
- experimental evaluation (lab-scale)
- initial demonstration using *in vitro* and *in vivo* models (not human trials)
- exploration of potential production mechanisms
- early-stage prototyping
- product development planning
- intellectual property protection*

**Key features**

**Business-led applications:**
- Duration – up to three years
- Maximum grant - £2.4m
- Funding proportion – up to 50% of total eligible project costs

**Academic-led applications:**
- Duration – up to three years
- Maximum grant – £3m
- Funding proportion – awarded at RCUK fEC rules

**Late-stage award**

This grant takes a well-developed concept and demonstrates its effectiveness in a relevant environment through:
- initial human proof-of-concept studies
- demonstration of clinical utility and effectiveness
- demonstration of safety and efficacy (including phase I and II clinical trials)
- development of production mechanisms
- prototyping
- market testing
- intellectual property protection*

**Key features**

**Business-led applications:**
- Duration – up to three years
- Maximum grant - £2.4m
- Funding proportion – up to 50% of total eligible project costs

**Academic-led applications:**
- Duration – no formal limit
- Maximum grant – no formal limit
- Funding proportion – awarded at RCUK fEC rules

*eligible cost for business-led applications only*
Other TSB Funding Opportunities

- **New Business Models in High Value Manufacturing**
  - Feasibility studies up to £33k 75% funded. Single company.
  - Live 11 March
  - Cross sector, cell therapy highlighted

- **Enhancing Manufacturing Through Automation**
  - EoI by 6 March. Projects of £0.5M-£2M 50% funding
  - All market sectors

- **Advanced Manufacturing Supply Chain Initiative**
  - BIS –led: Live 28 February. Up to £2M 50% funded project costs funded; cross sector; All market sectors
  - AND....
£8m: **Supporting regenerative medicines and cell therapies**

- 2 Stage competition; Business led, single company and CR+D
- 2 streams:
  - support for the preclinical and clinical development of regenerative medicine and cell therapies
  - support for the development of enabling platform tools and technologies.
- Proposals to address development issues such as **preclinical; formulation and delivery; clinical trials; scale-up and manufacturing**
- Or key platform technologies to address: **product safety and/or efficacy/manufacturing challenges**
- Opens 4 March, closes 17 April - more info in call document
- 50-60% funding for companies
_connecting with the KTNs